4-bromo-2-(2,2-dicyanoethenyl)thiophene | 214831-34-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-bromo-2-(2,2-dicyanoethenyl)thiophene
• 英文别名: 2-[(4-bromothiophen-2-yl)methylidene]propanedinitrile
• CAS: 214831-34-2
• 化学式: C₈H₃BrN₂S
• 分子量: 239.095
• InChiKey: GJASMJQSGRATBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(2,2-dicyanoethenyl)thiophene 在 ammonium acetate 作用下， 以 二乙二醇二甲醚 、 正丁醇 为溶剂， 反应 24.0h， 生成 4-amino-5-(4-bromothiophen-2-yl)-6-(3,4-dimethoxyphenyl)-7-(thiophen-2-yl)pyrido[2,3-d]pyrimidine
  参考文献：
  名称：

  5,6,7-Trisubstituted 4-Aminopyrido[2,3-d]pyrimidines as Novel Inhibitors of Adenosine Kinase

  摘要：

  The synthesis and structure-activity relationship of a series of 5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel nonnucleoside adenosine kinase inhibitors is described. A variety of alkyl, aryl, and heteroaryl substituents were found to be tolerated at the C5, C6, and C7 positions of the pyridopyrimidine core. These studies have led to the identification of analogues that are potent inhibitors of adenosine kinase with in vivo analgesic activity.

  DOI：

  10.1021/jm030327l
• 作为产物：
  描述：

  4-溴-2-噻吩甲醛 、 丙二腈 在 聚甘氨酸 作用下， 以 乙醇 、 水 为溶剂， 反应 0.5h， 以97%的产率得到4-bromo-2-(2,2-dicyanoethenyl)thiophene
  参考文献：
  名称：

  5,6,7-Trisubstituted 4-Aminopyrido[2,3-d]pyrimidines as Novel Inhibitors of Adenosine Kinase

  摘要：

  The synthesis and structure-activity relationship of a series of 5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel nonnucleoside adenosine kinase inhibitors is described. A variety of alkyl, aryl, and heteroaryl substituents were found to be tolerated at the C5, C6, and C7 positions of the pyridopyrimidine core. These studies have led to the identification of analogues that are potent inhibitors of adenosine kinase with in vivo analgesic activity.

  DOI：

  10.1021/jm030327l

文献信息

• 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
  申请人：Abbott Laboratories

  公开号：US06030969A1

  公开（公告）日：2000-02-29

  A compound having the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined, a method for inhibiting adenosine kinase by administering a compound thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, a method of treating cerebral ischemia, epilepsy, pain, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, and methods for preparation thereof.

  一种具有以下结构式##STR1##的化合物，其中R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5被定义，一种通过给予该化合物来抑制腺苷激酶的方法，一种包含所述化合物的治疗有效量与药用可接受载体结合的药物组合物，一种治疗大脑缺血、癫痫、疼痛、痛觉、炎症和败血症的方法，包括向需要此类治疗的哺乳动物给予该化合物的治疗有效量，以及其制备方法。
• 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS
  申请人：Abbott Laboratories

  公开号：EP0975633A1

  公开（公告）日：2000-02-02
• US6030969A
  申请人：——

  公开号：US6030969A

  公开（公告）日：2000-02-29
• [EN] 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINOPYRIDOL[2,3-D]PYRIMIDINE A TRISUBSTITUTION 5,6,7
  申请人：ABBOTT LABORATORIES

  公开号：WO1998046604A1

  公开（公告）日：1998-10-22

  (EN) A compound having formula (II) wherein R1, R2, R3, R4 and R5 are defined, a method for inhibiting adenosine kinase by administering a compound thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, a method of treating cerebral ischemia, epilepsy, pain, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, and methods for preparation thereof.(FR) Un composé représenté par la formule générale (II) où R1, R2, R3, R4 et R5 sont conformes à la description qui en est donnée dans la demande. Un procédé permettant d'inhiber l'adénosine kinase par administration d'un tel composé. Une composition pharmaceutique comprenant une quantité thérapeutiquement suffisante d'un tel composé en association avec un excipient pharmaceutiquement acceptable. Un traitement de l'ischémie cérébrale, de l'épilepsie, de la douleur, de la nociception, de l'inflammation, de la septicémie, dans le cas d'un mammifère nécessitant un tel traitement, lequel traitement consiste en l'administration, au mammifère considéré, d'une quantité thérapeutiquement suffisante d'un tel composé. Un procédé de préparation d'un tel composé.
• 5,6,7-Trisubstituted 4-Aminopyrido[2,3-<i>d</i>]pyrimidines as Novel Inhibitors of Adenosine Kinase
  作者：Richard J. Perner、Yu-Gui Gu、Chih-Hung Lee、Erol K. Bayburt、Jeffery McKie、Karen M. Alexander、Kathy L. Kohlhaas、Carol T. Wismer、Joe Mikusa、Michael F. Jarvis、Elizabeth A. Kowaluk、Shripad S. Bhagwat

  DOI：10.1021/jm030327l

  日期：2003.11.1

  The synthesis and structure-activity relationship of a series of 5,6,7-trisubstituted 4-aminopyrido[2,3-d]pyrimidines as novel nonnucleoside adenosine kinase inhibitors is described. A variety of alkyl, aryl, and heteroaryl substituents were found to be tolerated at the C5, C6, and C7 positions of the pyridopyrimidine core. These studies have led to the identification of analogues that are potent inhibitors of adenosine kinase with in vivo analgesic activity.